These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 21785750)

  • 1. Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month duration.
    Kim WJ; Park CY; Jeong EH; Seo JY; Seol JS; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Kim SW
    Diabetes Metab J; 2011 Jun; 35(3):290-7. PubMed ID: 21785750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
    Bloomgarden ZT; Tunceli K; Liu J; Brodovicz KG; Mavros P; Engel SS; Radican L; Chen Y; Rajpathak S; Qiu Y; Brudi P; Fonseca V
    J Diabetes; 2017 Jul; 9(7):677-688. PubMed ID: 27531167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
    Pérez-Monteverde A; Seck T; Xu L; Lee MA; Sisk CM; Williams-Herman DE; Engel SS; Kaufman KD; Goldstein BJ
    Int J Clin Pract; 2011 Sep; 65(9):930-8. PubMed ID: 21849007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study.
    Valensi P; de Pouvourville G; Benard N; Chanut-Vogel C; Kempf C; Eymard E; Moisan C; Dallongeville J
    Diabetes Metab; 2015 Jun; 41(3):231-8. PubMed ID: 25976701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus.
    Kim SA; Shim WH; Lee EH; Lee YM; Beom SH; Kim ES; Yoo JS; Nam JS; Cho MH; Park JS; Ahn CW; Kim KR
    Diabetes Metab J; 2011 Apr; 35(2):159-65. PubMed ID: 21738898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.
    Elkind-Hirsch KE; Paterson MS; Shaler D; Gutowski HC
    Endocr Pract; 2018 Apr; 24(4):361-368. PubMed ID: 29561188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
    Russell-Jones D; Cuddihy RM; Hanefeld M; Kumar A; González JG; Chan M; Wolka AM; Boardman MK;
    Diabetes Care; 2012 Feb; 35(2):252-8. PubMed ID: 22210563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Description of anti-diabetic drug utilization pre- and post-formulary restriction of sitagliptin: findings from a national health plan.
    Huang X; Liu Z; Shankar RR; Rajpathak S
    Curr Med Res Opin; 2015 Aug; 31(8):1495-500. PubMed ID: 26073703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probiotic B420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice.
    Stenman LK; Waget A; Garret C; Briand F; Burcelin R; Sulpice T; Lahtinen S
    Diabetol Metab Syndr; 2015; 7():75. PubMed ID: 26366205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus.
    Chung HS; Lee MK
    Diabetes Metab J; 2011 Aug; 35(4):411-7. PubMed ID: 21977462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin.
    Parker ED; Wittbrodt ET; McPheeters JT; Frias JP
    Diabetes Obes Metab; 2019 Feb; 21(2):227-233. PubMed ID: 30101553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients.
    Degli Esposti L; Saragoni S; Buda S; Degli Esposti E
    Clinicoecon Outcomes Res; 2014; 6():463-72. PubMed ID: 25364266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.
    Pasquel FJ; Gianchandani R; Rubin DJ; Dungan KM; Anzola I; Gomez PC; Peng L; Hodish I; Bodnar T; Wesorick D; Balakrishnan V; Osei K; Umpierrez GE
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):125-133. PubMed ID: 27964837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Diabetes Ther; 2015 Jun; 6(2):213-26. PubMed ID: 26014844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study.
    Goldshtein I; Karasik A; Melzer-Cohen C; Engel SS; Yu S; Sharon O; Brodovicz K; Gadir N; Katzeff HL; Radican L; Chodick G; Shalev V; Tunceli K
    J Diabetes Complications; 2016; 30(7):1354-9. PubMed ID: 27320183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients.
    Bando Y; Kanehara H; Aoki K; Hisada A; Toya D; Tanaka N
    J Diabetes Investig; 2012 Mar; 3(2):170-4. PubMed ID: 24843561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects.
    Fouqueray P; Perrimond-Dauchy S; Bolze S
    Clin Pharmacokinet; 2020 Oct; 59(10):1261-1271. PubMed ID: 32270440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.